Peshkova / Shutterstock.com
LSIPR’s Sarah Morgan investigates the current state of play of M&A in the sector and predicts the next year of activity.
Deal-making experienced a lull over the winter period last year, but this was the calm before the storm. A January 3 announcement from US pharmaceutical company Bristol-Myers Squibb (BMS) reignited a stream of mergers and acquisitions (M&A) activity in the life sciences space.
BMS revealed it would purchase Celgene, a drug manufacturer focusing on new cancer and inflammation treatments, for $74 billion.
It marked the start of a busy 2019, and was the first of seven megadeals (deals valued at $5 billion plus) announced in the first half of this year, according to PwC.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
M&A, life sciences, drug manufacturer, Celgene, megadeals, oncology, pharmaceuticals, AI, machine learning, innovative therapies, R&D, CAR-T, Brexit, tech